SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Merck Headquarters/iStock, JHVEPhoto
Business
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%
Merck’s bestselling immunotherapy raked in $6.9 billion in the first quarter of 2024. Analysts had been expecting $6.71 billion in Keytruda sales, according to estimates from FactSet.
April 25, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Man prepares his GLP-1 receptor agonist injection
Policy
Wegovy’s New Heart Indication to Expand Medicare Coverage for 3.6M Beneficiaries: KFF
A report from the Kaiser Family Foundation estimates that the FDA’s recent approval of Novo Nordisk’s Wegovy to reduce the risk of heart attack and stroke in people with cardiovascular disease will open Medicare coverage to one in four beneficiaries with obesity.
April 24, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Nasdaq headquarters in New York/iStock,
Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
April 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Illustration of neurological health concept
Drug Development
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
April 17, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: An artist’s illustration of mental health concept
Drug Development
Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug
Already approved in schizophrenia and bipolar depression, Intra-Cellular Therapies reported strong late-stage data Tuesday for its antipsychotic Caplyta in major depressive disorder.
April 16, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Downward arrow in graph showing stock price dropping
Drug Development
Enlivex’s Stock Plummets 50% on Phase II Sepsis Results for Cell Therapy
Investors were disappointed in data from a mid-stage study of Enlivex Therapeutics’ Allocetra cell therapy for the treatment of sepsis. The Israeli company is considering a follow-on trial in sepsis caused by urinary tract infection.
April 12, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: A smartphone analyzing sound
Drug Development
Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
April 12, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Empty pill packs tossed together in a pile
Drug Development
US Drug Shortages Reach All-Time High Since 2001: Report
The American Society of Health-System Pharmacists has released statistics showing the number of active and ongoing U.S. drug shortages has reached 323, the highest number since it began tracking the data.
April 11, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers
Drug Development
FDA Backs BrainStorm’s Design for Phase IIIb Trial in Early-Stage ALS
After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.
April 9, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: San Diego over abstract cancer cell background
Networking, ADCs and Early Science on the Agenda at AACR 2024
Analysts and attendees aren’t expecting groundbreaking data at the American Association for Cancer Research’s annual conference this year, but for many, that isn’t the point.
April 4, 2024
 · 
3 min read
 · 
Kate Goodwin
Pictured: Illustration of an antibody on blue background
Business
Diagonal Therapeutics Nets $128M for New Approach to Agonist Antibodies
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
April 3, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Cancer Vaccine
Drug Development
Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering
The biotech’s personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm. Gritstone blames trial protocol and plans for a Phase III study.
April 2, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Collage of woman taking a pill with water
Drug Development
Will Oral Weight-Loss Drugs Break Open an Already Lucrative Market?
Now in Phase III with its small molecule orforglipron, Eli Lilly is leading the oral GLP-1 race against Novo Nordisk, Pfizer, Roche and others.
March 28, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Merck building and sign in Silicon Valley
Policy
EU Approves Merck’s Keytruda, Chemo Combo for Lung Cancer
Keytruda can now be used in the European Union for patients with resectable non-small cell lung cancer at high risk of recurrence in combination with platinum chemotherapy, then continued as a monotherapy afterwards.
March 28, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Analyst pointing to stock chart / iStock
Drug Development
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing
Stoke Therapeutics reported results for Dravet syndrome studies showing clinically meaningful effects, including reductions in convulsive seizure frequency, supporting the potential for disease modification.
March 26, 2024
 · 
2 min read
 · 
Kate Goodwin
Load More